Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
Luca Bollo, Tommaso Guerra, Davide Fiore Bavaro, Laura Monno, Annalisa Saracino, Gioacchino Angarano, Damiano Paolicelli, María Trojano, Pietro Iaffaldano
Topics & Concepts
FingolimodMultiple sclerosisTeriflunomideCoronavirus disease 2019 (COVID-19)MedicineSeroconversionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pandemic2019-20 coronavirus outbreakInternal medicineVirologyImmunologyDiseaseVirusOutbreakInfectious disease (medical specialty)Multiple Sclerosis Research StudiesInflammasome and immune disordersPeripheral Neuropathies and Disorders